Editorial
Copyright ©2013 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Radiol. Dec 28, 2013; 5(12): 450-454
Published online Dec 28, 2013. doi: 10.4329/wjr.v5.i12.450
Interventional neuroradiology of stroke, still not dead
Vitor Mendes Pereira, Karl-Olof Lövblad
Vitor Mendes Pereira, Karl-Olof Lövblad, Department of Diagnostic and Interventional Neuroradiology, Geneva University Hospitals, 1224 Geneva, Switzerland
Author contributions: Pereira VM wrote the manuscript; Lövblad KO discussed and revised the manuscript.
Correspondence to: Karl-Olof Lövblad, MD, Department of Diagnostic and Interventional Neuroradiology, Geneva University Hospitals, 4 rue Gabrielle-Perret-Gentil, 1224 Geneva, Switzerland. karl-olof.lovblad@hcuge.ch
Telephone: +41-22-3727033 Fax: +41-22-3727072
Received: May 28, 2013
Revised: November 11, 2013
Accepted: November 15, 2013
Published online: December 28, 2013

Abstract

Since the National Institute of Neurological Disorders and Stroke trial, intravenous thrombolysis has been gaining wide acceptance as the modality of treatment for acute embolic stroke, with a current therapeutic window of up to 4.5 h. Both imaging [with either magnetic resonance imaging (MRI) or computed tomography (CT)] and interventional techniques (thrombolysis and/or thrombectomy) have since improved and provided us with additional imaging of the penumbra using CT or MRI and more advanced thrombolysis or thrombectomy strategies that have been embraced in many centers dealing with patients with acute cerebral ischemia. These techniques, however, have come under scrutiny due to their accrued healthcare costs and have been questioned following major recent studies. These studies basically showed that interventional techniques were not superior to the traditional intravenous thrombolysis techniques and that penumbra imaging could not determine what patients would benefit from more aggressive (i.e., interventional) treatment. We discuss this in the light of the latest developments in both diagnostic and interventional neuroradiology and point out why further studies are needed in order to define the right choices for patients with acute stroke. Indeed, these studies were in part conducted with suboptimal patient recruitment strategies and did not always use the latest interventional techniques available today. So, while these studies may have raised some relevant questions, at the same time, definitive answers have not been given, in our opinion.

Key Words: Stroke, Interventional neuroradiology thrombolysis, Magnetic resonance imaging, Computed tomography

Core tip: While intravenous thrombolysis has gained wide acceptance as a major breakthrough for the acute treatment of stroke, interventional and diagnostic neuroradiology tools have also evolved at a very high rate, providing us with very sophisticated techniques to demonstrate brain tissue damage and revascularization techniques. However, these methods have not been evaluated properly until recently and have been adopted quickly by part of the clinical neuroscience community. A number of recent studies question the impact of these techniques.



INTERVENTIONAL NEURORADIOLOGY OF STROKE-STILL NOT DEAD

The position of diagnostic neuroradiology and interventional neuroradiology and their role in stroke have been questioned recently by some randomized controlled studies[1-4]. The role and position of imaging in the diagnosis and management of stroke has changed extensively since the 1990s. Overall, stroke and its management have changed drastically: while initially patients were considered to be future candidates for reeducation if they survived, with new advances in the management this perspective has changed considerably. Indeed, the concept of stroke units where these patients were seen with an emphasis on their acute disease has already improved their outcome significantly. Then, thrombolysis was introduced with groundbreaking results following the National Institute of Neurological Disorders and Stroke trials[5-7]; initially this implied a rather strict therapeutic window, as well as the sole intravenous administration of drugs and with the presence of significant potential complications due to treatment, such as hemorrhage. Thus, strict guidelines for the management of patients with stroke have been developed in order to improve management and outcomes[8]. However, during that same decade, the radiological side, both diagnostic and interventional techniques, evolved in ways that were important: in a period of a few years, we additionally had diffusion magnetic resonance imaging (MRI)[9], perfusion computed tomography (CT)[10] and additional interventional procedures, such as local intra-arterial thrombolysis[11], followed by mechanical thrombectomy and stenting[12]. On the one hand, dramatic increases were observed in advances that led to an improved understanding of the acute disease and eventually its treatment. However, while the initial results were encouraging, their use was also more time and money consuming, all without real state of the art validation. For anyone who has been involved in the management, diagnosis and treatment of these patients, it is important to know that we saw advances in a very short period in patients where before nothing was expected. This also caused a shift from stroke being a globally managed disease to one that would be more reasonably treated within specialized stroke units and centers. Thus, in addition to a higher technicality and cost, there was a shift away from the primary gatekeepers, the general practitioners or internists, because if time was more and more brain, it meant that these patients had to have a change in clinical pathway for which not everyone was ready. Therapy was moving fast, while at the same time the scientific evidence was not and this was bound to make the whole system collapse. Fortunately, we are not at that point but the recently published papers in the New England Journal raise some valid points while being inherently flawed.

Interventional neuroradiology, different to medical pharmaceutical treatments, does inherently rely on not being fully standardizable; indeed, in order to obtain a certain level of quality, a certain number of interventions must be performed at the center to assure a good level as well as the whole chain from the arrival at the hospital to the post-operative management. Acute stroke treatment is, in fact, a process that involves different disciplines, divisions and teams at the health network and hospital. High volume centers mean that they are able to bring patients through the detection of stroke, diagnosis and therapeutic steps constantly that imply increased effectiveness over time. If we consider a stroke treatment study, where the acute treatment is evaluated but, in fact, the whole stroke pathway is involved, it is hard to imagine that low volume or inexperienced centers will be able to demonstrate any difference between any kinds of treatment. While a drug such as aspirin can be given by any physician or nurse in a standardized way, this is unfortunately not the case with interventional techniques which, like surgery, rely on expertise (relying on experience and talent) which is also at the same time difficult or impossible to quantify. Thus, to some degree, per se interventional techniques are not best suited to fully randomized studies and are almost always certain to fail. We did read with interest the two recent papers published in the New England Journal of Medicine[13,14] as well as the accompanying editorial[4]. What is worrisome is the potential message that these papers may send out: that interventional therapy as such is a failure in improving outcomes in stroke. The introduction of intravenous thrombolysis was a breakthrough for patients with cerebral ischemia, but clinicians, investigators and patients have been frustrated by the limitations due to the rather limited time window and even associated potential complications if exclusion criteria were not followed. Indeed, even with improved outcomes, a high number of hemorrhagic events have been observed with thrombolysis, forcing many clinicians to look for another alternative therapy that might induce less bleeding. There has also been a striking lack of translation of the knowledge about ischemic events into daily practice due to the failure of any kind of alternative neuroprotective therapy to function clinically. Besides simple intravenous thrombolysis based on the exclusion of other pathologies, many investigators have over the years explored the use of imaging for the detection of still viable tissue and the use of interventional techniques. Anybody who has been confronted with utilizing these methods has been able to see that they have indeed improved patient management to some degree, maybe not to the degree we would like, but at least substantially. A further paper also questioned the use of advanced imaging techniques to help identify patients using penumbra imaging in order to determine what candidates may be best suited for another type of therapy. This is an excellent idea but fails, probably because it did only look at penumbral patterns, whereas when one looks at imaging findings, it is very often important to take all parameters into account and additionally look at the parenchyma (on diffusion weighted imaging or unenhanced CT) and the angiographic appearance of the vessels; indeed, this last factor should not be underappreciated since thrombolysis or thrombectomy target the vessel. However, both CT and MRI have become powerful techniques, at least for the exclusion of hemorrhage and the detection of an early insult[15,16]. Despite the fact that both MR and CT techniques have been able to provide more information than merely the absence or presence of hemorrhage, the main role of imaging is still central to exclude another pathology before initiating treatment. Indeed, one area where the role of neuroimaging has always been more problematic, has been with regard to what we call the penumbra[17,18]. From a theoretical point of view, the penumbra is a state of hypoperfusion associated with synaptic dysfunction but not yet membrane dysfunction[19-22]; thus, this is a state where the neurons are not able to function normally but may recover if flow is recovered. The penumbra that we see on imaging with either MRI[22-37] or CT[38-48] is, due to methodological factors, not a representation of the real penumbra as most people understand it: instead of having a pure metabolic model, we have a model based on hemodynamics and which has limitations whether one uses CT or MRI. The validation of these techniques have been rendered more difficult by the fact that most centers use home-made software that is constantly evolving[49,50] and, while these limitations exist, the technique has been shown to be useful. Indeed, very often, one can demonstrate a larger than expected area of hypoperfusion and sometimes demonstrate other causes that may mimic strokes[51]. Interventional techniques can be time-consuming and prone to potential complications but, if used early on in a setting where the angiography suite is placed ideally close to the emergency room or where the time to puncture can be reduced[52,53], definitely has great value. Indeed, the technique, since it includes angiography with direct luminography of the affected vessel, also allows direct visualization of the thrombus as well as vascular revascularization. Additionally, over the last decade, we have moved from pharmacological local intra-arterial fibrinolysis to more complex interventions requiring stenting and/or clot retrieval systems. The evolution of these techniques that have become more efficient, safer and easier to use has been striking over the last few years. This is unfortunately the period when most of the randomized studies were conducted in centers with low volume or with no significant experience of interventional treatment (we can see this by the recruitment numbers and the techniques and devices used in those studies). Thus, it does not represent the results obtained with current state of the art interventional techniques. These studies are a call to sobriety and show us that we should probably not be too enthusiastic when looking at single patient data compared to larger studies. We are, however, in an era where interventional neuroradiology is trying to become more evidence-based but in order to do so, it has to provide larger series than those presented to date, taking into account the very impressive technological advances we have seen recently, and maybe then more encouraging results can be produced. On the one hand, the studies are not encouraging but they represent the first attempts at investigating interventional stroke therapies with state of the art statistics. What the studies maybe lack in “patient selection criteria”, they make up for in study design. Indeed, the recent years or months have seen a shift from aspiration to thrombectomy using stent retrievers with a rapidity that requires that they be taken into account before making a final assessment of the method[4]. The fact that most of the studies, including the recently published randomized ones, put techniques that are completely different into the same basket. Recent studies demonstrated that there are two generations of devices to date and their results are completely different (swift and trevo 2). How can we analyze data using those two generation devices together? Or how can we consider the results of a study using techniques that have not been used on high volume and experienced centers for at least 3-4 years? It is not the fault of those responsible for the studies as they declared they had many issues in order to include high volume centers, to keep a constant and unbiased recruitment, and with many competitive studies. The high volume centers that refused to randomize patients in the past are paying an expensive price now that intra-arterial therapy is being proven. This, in parallel with constant evolution in imaging and post-processing techniques, has made it difficult sometimes to evaluate the situation in the way it still merits before being relegated to history. Thus, efforts should focus on designing further studies involving centers of excellence with a high flow of patients and where time to treatment is reduced to a minimum; then it will be possible to obtain data as homogenous as possible in order to fully appreciate the efficacy of endovascular management of stroke. We feel that, in the worst case, these techniques may be used for a while for more extensive clots but this may be proven wrong if studies are conducted in a more fair way.

Only when new studies have been performed with more relevant study criteria (faster inclusion times, faster time to needle, done in centers with high volumes etc.) can we really appreciate the failures and successes of interventional neuroradiology coupled by modern imaging techniques used in a correct way[54]; these paradigms may require using many parameters in order to function correctly[55]. Only then can we avoid being too distracted by the main problem we may still encounter, that the technologies keep evolving in this field faster than the evaluation, thus making validation difficult.

Footnotes

P- Reviewer: Alexander MD S- Editor: Zhai HH L- Editor: Roemmele A E- Editor: Liu SQ

References
1.  Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, Feng L, Meyer BC, Olson S, Schwamm LH. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med. 2013;368:914-923.  [PubMed]  [DOI]
2.  Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, Jauch EC, Jovin TG, Yan B, Silver FL, von Kummer R, Molina CA, Demaerschalk BM, Budzik R, Clark WM, Zaidat OO, Malisch TW, Goyal M, Schonewille WJ, Mazighi M, Engelter ST, Anderson C, Spilker J, Carrozzella J, Ryckborst KJ, Janis LS, Martin RH, Foster LD, Tomsick TA; Interventional Management of Stroke (IMS) III Investigators. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med. 2013;368:893-903.  [PubMed]  [DOI]
3.  Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, Boccardi E. Endovascular treatment for acute ischemic stroke. N Engl J Med. 2013;368:904-913.  [PubMed]  [DOI]
4.  Chimowitz MI. Endovascular treatment for acute ischemic stroke--still unproven. N Engl J Med. 2013;368:952-955.  [PubMed]  [DOI]
5.  Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333:1581-1587.  [PubMed]  [DOI]
6.  Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Höxter G, Mahagne MH. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.  [PubMed]  [DOI]
7.  Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, Larrue V, Lees KR, Medeghri Z, Machnig T. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.  [PubMed]  [DOI]
8.  Adams HP, del Zoppo G, Alberts MJ, Bhatt DL, Brass L, Furlan A, Grubb RL, Higashida RT, Jauch EC, Kidwell C. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke. 2007;38:1655-1711.  [PubMed]  [DOI]
9.  Lövblad KO, Laubach HJ, Baird AE, Curtin F, Schlaug G, Edelman RR, Warach S. Clinical experience with diffusion-weighted MR in patients with acute stroke. AJNR Am J Neuroradiol. 1998;19:1061-1066.  [PubMed]  [DOI]
10.  Wintermark M, Sincic R, Sridhar D, Chien JD. Cerebral perfusion CT: technique and clinical applications. J Neuroradiol. 2008;35:253-260.  [PubMed]  [DOI]
11.  Gönner F, Remonda L, Mattle H, Sturzenegger M, Ozdoba C, Lövblad KO, Baumgartner R, Bassetti C, Schroth G. Local intra-arterial thrombolysis in acute ischemic stroke. Stroke. 1998;29:1894-1900.  [PubMed]  [DOI]
12.  Pereira VM, Narata AP, Gonzalez AM, Sztajzel R, Lovblad KO. Use of stentrievers in acute stroke: tips, tricks, and current results. Tech Vasc Interv Radiol. 2012;15:68-77.  [PubMed]  [DOI]
13.  Warach S, Pettigrew LC, Dashe JF, Pullicino P, Lefkowitz DM, Sabounjian L, Harnett K, Schwiderski U, Gammans R. Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators. Ann Neurol. 2000;48:713-722.  [PubMed]  [DOI]
14.  Dávalos A, Alvarez-Sabín J, Castillo J, Díez-Tejedor E, Ferro J, Martínez-Vila E, Serena J, Segura T, Cruz VT, Masjuan J. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012;380:349-357.  [PubMed]  [DOI]
15.  Kidwell CS, Chalela JA, Saver JL, Starkman S, Hill MD, Demchuk AM, Butman JA, Patronas N, Alger JR, Latour LL. Comparison of MRI and CT for detection of acute intracerebral hemorrhage. JAMA. 2004;292:1823-1830.  [PubMed]  [DOI]
16.  Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, Hill MD, Patronas N, Latour L, Warach S. Magnetic resonance imaging and computed tomography in emergency assessment of patients with suspected acute stroke: a prospective comparison. Lancet. 2007;369:293-298.  [PubMed]  [DOI]
17.  Astrup J, Symon L, Branston NM, Lassen NA. Cortical evoked potential and extracellular K+ and H+ at critical levels of brain ischemia. Stroke. 1977;8:51-57.  [PubMed]  [DOI]
18.  Astrup J, Siesjö BK, Symon L. Thresholds in cerebral ischemia - the ischemic penumbra. Stroke. 1981;12:723-725.  [PubMed]  [DOI]
19.  Symon L, Astrup J. Phenomena associated with focal ischaemia in the central nervous system. Acta Neurochir Suppl (Wien). 1979;28:215-217.  [PubMed]  [DOI]
20.  Fisher M, Takano K. The penumbra, therapeutic time window and acute ischaemic stroke. Baillieres Clin Neurol. 1995;4:279-295.  [PubMed]  [DOI]
21.  Touzani O, Roussel S, MacKenzie ET. The ischaemic penumbra. Curr Opin Neurol. 2001;14:83-88.  [PubMed]  [DOI]
22.  Heiss WD, Forsting M, Diener HC. Imaging in cerebrovascular disease. Curr Opin Neurol. 2001;14:67-75.  [PubMed]  [DOI]
23.  Kidwell CS, Villablanca JP, Saver JL. Advances in neuroimaging of acute stroke. Curr Atheroscler Rep. 2000;2:126-135.  [PubMed]  [DOI]
24.  Schlaug G, Benfield A, Baird AE, Siewert B, Lövblad KO, Parker RA, Edelman RR, Warach S. The ischemic penumbra: operationally defined by diffusion and perfusion MRI. Neurology. 1999;53:1528-1537.  [PubMed]  [DOI]
25.  Baird AE, Benfield A, Schlaug G, Siewert B, Lövblad KO, Edelman RR, Warach S. Enlargement of human cerebral ischemic lesion volumes measured by diffusion-weighted magnetic resonance imaging. Ann Neurol. 1997;41:581-589.  [PubMed]  [DOI]
26.  Baird AE, Lövblad KO, Dashe JF, Connor A, Burzynski C, Schlaug G, Straroselskaya I, Edelman RR, Warach S. Clinical correlations of diffusion and perfusion lesion volumes in acute ischemic stroke. Cerebrovasc Dis. 2000;10:441-448.  [PubMed]  [DOI]
27.  Wu O, Koroshetz WJ, Ostergaard L, Buonanno FS, Copen WA, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM. Predicting tissue outcome in acute human cerebral ischemia using combined diffusion- and perfusion-weighted MR imaging. Stroke. 2001;32:933-942.  [PubMed]  [DOI]
28.  Ay H, Buonanno FS, Rordorf G, Schaefer PW, Schwamm LH, Wu O, Gonzalez RG, Yamada K, Sorensen GA, Koroshetz WJ. Normal diffusion-weighted MRI during stroke-like deficits. Neurology. 1999;52:1784-1792.  [PubMed]  [DOI]
29.  Sorensen AG, Copen WA, Ostergaard L, Buonanno FS, Gonzalez RG, Rordorf G, Rosen BR, Schwamm LH, Weisskoff RM, Koroshetz WJ. Hyperacute stroke: simultaneous measurement of relative cerebral blood volume, relative cerebral blood flow, and mean tissue transit time. Radiology. 1999;210:519-527.  [PubMed]  [DOI]
30.  González RG, Schaefer PW, Buonanno FS, Schwamm LH, Budzik RF, Rordorf G, Wang B, Sorensen AG, Koroshetz WJ. Diffusion-weighted MR imaging: diagnostic accuracy in patients imaged within 6 hours of stroke symptom onset. Radiology. 1999;210:155-162.  [PubMed]  [DOI]
31.  Schwamm LH, Koroshetz WJ, Sorensen AG, Wang B, Copen WA, Budzik R, Rordorf G, Buonanno FS, Schaefer PW, Gonzalez RG. Time course of lesion development in patients with acute stroke: serial diffusion- and hemodynamic-weighted magnetic resonance imaging. Stroke. 1998;29:2268-2276.  [PubMed]  [DOI]
32.  Rordorf G, Koroshetz WJ, Copen WA, Cramer SC, Schaefer PW, Budzik RF, Schwamm LH, Buonanno F, Sorensen AG, Gonzalez G. Regional ischemia and ischemic injury in patients with acute middle cerebral artery stroke as defined by early diffusion-weighted and perfusion-weighted MRI. Stroke. 1998;29:939-943.  [PubMed]  [DOI]
33.  Sorensen AG, Buonanno FS, Gonzalez RG, Schwamm LH, Lev MH, Huang-Hellinger FR, Reese TG, Weisskoff RM, Davis TL, Suwanwela N. Hyperacute stroke: evaluation with combined multisection diffusion-weighted and hemodynamically weighted echo-planar MR imaging. Radiology. 1996;199:391-401.  [PubMed]  [DOI]
34.  Warach S, Dashe JF, Edelman RR. Clinical outcome in ischemic stroke predicted by early diffusion-weighted and perfusion magnetic resonance imaging: a preliminary analysis. J Cereb Blood Flow Metab. 1996;16:53-59.  [PubMed]  [DOI]
35.  Schellinger PD, Bryan RN, Caplan LR, Detre JA, Edelman RR, Jaigobin C, Kidwell CS, Mohr JP, Sloan M, Sorensen AG. Evidence-based guideline: The role of diffusion and perfusion MRI for the diagnosis of acute ischemic stroke: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2010;75:177-185.  [PubMed]  [DOI]
36.  Staroselskaya IA, Chaves C, Silver B, Linfante I, Edelman RR, Caplan L, Warach S, Baird AE. Relationship between magnetic resonance arterial patency and perfusion-diffusion mismatch in acute ischemic stroke and its potential clinical use. Arch Neurol. 2001;58:1069-1074.  [PubMed]  [DOI]
37.  Kidwell CS, Saver JL, Mattiello J, Starkman S, Vinuela F, Duckwiler G, Gobin YP, Jahan R, Vespa P, Kalafut M. Thrombolytic reversal of acute human cerebral ischemic injury shown by diffusion/perfusion magnetic resonance imaging. Ann Neurol. 2000;47:462-469.  [PubMed]  [DOI]
38.  Röther J. CT and MRI in the diagnosis of acute stroke and their role in thrombolysis. Thromb Res. 2001;103 Suppl 1:S125-S133.  [PubMed]  [DOI]
39.  Wintermark M, Reichhart M, Cuisenaire O, Maeder P, Thiran JP, Schnyder P, Bogousslavsky J, Meuli R. Comparison of admission perfusion computed tomography and qualitative diffusion- and perfusion-weighted magnetic resonance imaging in acute stroke patients. Stroke. 2002;33:2025-2031.  [PubMed]  [DOI]
40.  Wintermark M, Reichhart M, Thiran JP, Maeder P, Chalaron M, Schnyder P, Bogousslavsky J, Meuli R. Prognostic accuracy of cerebral blood flow measurement by perfusion computed tomography, at the time of emergency room admission, in acute stroke patients. Ann Neurol. 2002;51:417-432.  [PubMed]  [DOI]
41.  Meuli RA. Imaging viable brain tissue with CT scan during acute stroke. Cerebrovasc Dis. 2004;17 Suppl 3:28-34.  [PubMed]  [DOI]
42.  Michel P, Reichhart M, Wintermark M, Meuli R, Bogousslavsky J. Perfusion-CT guided acute stroke management. Rinsho Shinkeigaku. 2003;43:728-731.  [PubMed]  [DOI]
43.  Wintermark M, Fischbein NJ, Smith WS, Ko NU, Quist M, Dillon WP. Accuracy of dynamic perfusion CT with deconvolution in detecting acute hemispheric stroke. AJNR Am J Neuroradiol. 2005;26:104-112.  [PubMed]  [DOI]
44.  Wintermark M. Brain perfusion-CT in acute stroke patients. Eur Radiol. 2005;15 Suppl 4:D28-D31.  [PubMed]  [DOI]
45.  Schaefer PW, Roccatagliata L, Ledezma C, Hoh B, Schwamm LH, Koroshetz W, Gonzalez RG, Lev MH. First-pass quantitative CT perfusion identifies thresholds for salvageable penumbra in acute stroke patients treated with intra-arterial therapy. AJNR Am J Neuroradiol. 2006;27:20-25.  [PubMed]  [DOI]
46.  Parsons MW, Pepper EM, Bateman GA, Wang Y, Levi CR. Identification of the penumbra and infarct core on hyperacute noncontrast and perfusion CT. Neurology. 2007;68:730-736.  [PubMed]  [DOI]
47.  Wintermark M, Meuli R, Browaeys P, Reichhart M, Bogousslavsky J, Schnyder P, Michel P. Comparison of CT perfusion and angiography and MRI in selecting stroke patients for acute treatment. Neurology. 2007;68:694-697.  [PubMed]  [DOI]
48.  Sparacia G, Iaia A, Assadi B, Lagalla R. Perfusion CT in acute stroke: predictive value of perfusion parameters in assessing tissue viability versus infarction. Radiol Med. 2007;112:113-122.  [PubMed]  [DOI]
49.  Abels B, Villablanca JP, Tomandl BF, Uder M, Lell MM. Acute stroke: a comparison of different CT perfusion algorithms and validation of ischaemic lesions by follow-up imaging. Eur Radiol. 2012;22:2559-2567.  [PubMed]  [DOI]
50.  Soares BP, Dankbaar JW, Bredno J, Cheng S, Bhogal S, Dillon WP, Wintermark M. Automated versus manual post-processing of perfusion-CT data in patients with acute cerebral ischemia: influence on interobserver variability. Neuroradiology. 2009;51:445-451.  [PubMed]  [DOI]
51.  Hand PJ, Kwan J, Lindley RI, Dennis MS, Wardlaw JM. Distinguishing between stroke and mimic at the bedside: the brain attack study. Stroke. 2006;37:769-775.  [PubMed]  [DOI]
52.  Gupta R, Horev A, Nguyen T, Gandhi D, Wisco D, Glenn BA, Tayal AH, Ludwig B, Terry JB, Gershon RY. Higher volume endovascular stroke centers have faster times to treatment, higher reperfusion rates and higher rates of good clinical outcomes. J Neurointerv Surg. 2013;5:294-297.  [PubMed]  [DOI]
53.  Sun CH, Nogueira RG, Glenn BA, Connelly K, Zimmermann S, Anda K, Camp D, Frankel MR, Belagaje SR, Anderson AM. “Picture to puncture”: a novel time metric to enhance outcomes in patients transferred for endovascular reperfusion in acute ischemic stroke. Circulation. 2013;127:1139-1148.  [PubMed]  [DOI]
54.  Donnan GA, Davis SM. Neuroimaging, the ischaemic penumbra, and selection of patients for acute stroke therapy. Lancet Neurol. 2002;1:417-425.  [PubMed]  [DOI]
55.  Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, Barber PA, Parsons M, Darby D, Davis S. A three-item scale for the early prediction of stroke recovery. Lancet. 2001;357:2095-2099.  [PubMed]  [DOI]